EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes

Geremia B Bolli iD, Francesca Porcellati, Paola Lucidi, Carmine G Fanelli iD, Gianluca Perseghin, Michael Horowitz, David R Owens iD

Diabetes, Obesity and Metabolism · 2025-08 · 27 (S7) · 14-25

DOI: 10.1111/dom.16616 ↗

At a glance

Übersichtsarbeit in Diabetes, Obesity and Metabolism, published online on 2025-07-17. Written by Geremia B Bolli and 6 co-authors. Institution: Department of Medicine and Surgery, Perugia University Medical School, Perugia, Italy. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin. Cited 5 times so far (Crossref); 81 references. The full text is freely available (open access, CC BY 4.0). Funded by: University of Perugia, MUR -PRIN, Università degli Studi di Perugia.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). BI and GLP‐1RAs can be administered separately or as fixed‐ratio combinations (FRCs) for daily use (degludec+liraglutide, IDegLira, glargine‐100 + lixisenatide iGlarLixi) or weekly use (icodec+semaglutide, IcoSema). The currently available FRCs IDegLira and iGlarLixi differ in their respective BI as well as GLP‐1RA components. Liraglutide predominantly stimulates glucose‐dependent endogenous insulin secretion in response to nutrient challenges. In contrast, the rapid‐acting lixisenatide primarily delays gastric emptying over a few hours post‐dosing with little or no impact on insulin secretion. IDegLira in DUAL studies and iGlarLixi in LixiLan studies appear to have equivalent lowering effects on HbA1c, although IDegLira achieves a greater reduction in body weight. The weekly FRC IcoSema is superior to weekly insulin icodec (COMBINE 1), to semaglutide (COMBINE 2), and non‐inferior to basal‐bolus insulin therapy (COMBINE 3). Comparison of IcoSema with glargine‐100 is ongoing (COMBINE 4). However, all FRCs are limited by the low GLP‐1RA dose relative to the insulin delivered. Whenever higher GLP‐1RA doses are required (i.e., in obese people), the option of separate dosing of BI and GLP‐1RA with independent titration of each component should be considered.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinHumansRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsDrug CombinationsInsulin GlargineInsulin, Long-ActingLiraglutideDrug Therapy, CombinationGlucagon-Like PeptidesPeptidesBlood GlucoseGlucagon-Like Peptide-2 ReceptorGlucagon-Like Peptide 1Semaglutide

Author keywords

GLP‐1RAbasal insulinfixed‐ratio combinations basal insulin GLP‐1RAstype 2 diabetes

Substances

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsDrug CombinationsInsulin GlargineInsulin, Long-ActingLiraglutideGlucagon-Like PeptidesPeptidesInsulinBlood Glucose

Authors and institutions

  • Department of Medicine and Surgery, Perugia University Medical School, Perugia, Italy.
  • Centro Diabetologia Asl 2 Umbria 'Centro Storico', Foligno, Italy.
  • Department of Medicine and Surgery, Università degli Studi di Milano Bicocca & Policlinico, di Monza, Monza, Italy.
  • Endocrine and Metabolic Unit, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.
  • Cardiff University Medical School, Cardiff, UK.

ORCID profiles: Geremia B Bolli, Carmine G Fanelli, David R Owens

Funding

  • University of Perugia
  • MUR -PRIN
  • Università degli Studi di Perugia

Cite

APA

Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025). An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 27(S7), 14-25. https://doi.org/10.1111/dom.16616

Vancouver

Bolli GB, Porcellati F, Lucidi P, Fanelli CG, Perseghin G, Horowitz M, et al. An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025;27(S7):14-25. doi:10.1111/dom.16616

BibTeX
@article{Bolli2025,
  author = {Bolli, Geremia B and Porcellati, Francesca and Lucidi, Paola and Fanelli, Carmine G and Perseghin, Gianluca and Horowitz, Michael and Owens, David R},
  title = {An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {S7},
  pages = {14--25},
  doi = {10.1111/dom.16616}
}
Start for free →